Page 7 - Flipbook

PURE-01

• Patients – cT2-4aN0M scheduled for RC. 2018

amendment allowed for predominant variant histology

• Design – Phase 2 single armed trial

• Intervention – three courses of 200mg pembrolizumab

q3w preceding RC

• Outcomes– pT0 rate and pT ≤ 1 rate

• Updated analysis – Association between variants and

biomarkers and pathologic outcomes